Literature DB >> 19226410

Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

E Rosenthal1, D Salmon-Céron, C Lewden, V Bouteloup, G Pialoux, F Bonnet, M Karmochkine, T May, M François, C Burty, E Jougla, D Costagliola, P Morlat, G Chêne, P Cacoub.   

Abstract

BACKGROUND: More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS: In 2005, 34 departments prospectively recorded all deaths in HIV-infected patients who were followed in those departments (around 24 000).
RESULTS: were compared with those of four previous cross-sectional surveys conducted since 1995 using the same methodology. Results Among 287 reported deaths in 2005, 100 (35%) were related to AIDS, and 48 (17%) to ESLD. Three out of four patients who died from ESLD-related causes had chronic hepatitis C. Excessive alcohol consumption was reported in approximately half of the patients (48%). At death, 62% of patients had undetectable HIV viral load and the median CD4 count was 237 cells/microL. From 1995 to 2005, the proportion of deaths caused by ESLD increased from 2 to 17% (P<0.001). The proportion of deaths caused by hepatocellular carcinoma increased from 5% in 1995 to 25% in 2005 (P=0.0337).
CONCLUSIONS: Over the 10 years from 1995 to 2005, the proportion of deaths caused by hepatitis C virus-related ESLD has increased in HIV-infected patients. ESLD is currently a leading cause of death in this population, with hepatocellular carcinoma representing a quarter of liver-related deaths. Recommendations for the detection of hepatocellular carcinoma should be strictly applied in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226410     DOI: 10.1111/j.1468-1293.2008.00686.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  32 in total

Review 1.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

2.  Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?

Authors:  Brian Conway; Harout Tossonian
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

3.  Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement.

Authors:  Deborah S Hasin; Efrat Aharonovich; Ann O'Leary; Eliana Greenstein; Martina Pavlicova; Srikesh Arunajadai; Rachel Waxman; Milton Wainberg; John Helzer; Barbara Johnston
Journal:  Addiction       Date:  2013-04-17       Impact factor: 6.526

4.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

5.  Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting.

Authors:  C William Wester; John R Koethe; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Hwanhee Hong; Hermann Bussmann; Tendani Gaolathe; Catherine C McGowan; Timothy R Sterling; Richard G Marlink
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

6.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

7.  Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.

Authors:  Nora T Oliver; Christine M Hartman; Jennifer R Kramer; Elizabeth Y Chiao
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

8.  No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.

Authors:  Megan Crane; Sunee Sirivichayakul; J Judy Chang; Anchalee Avihingsanon; Sasiwimol Ubolyam; Supranee Buranapraditkun; Pattarawat Thantiworasit; Fiona Wightman; Stephen Locarnini; Gail Matthews; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

9.  The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.

Authors:  Marc-Arthur Loko; Dominique Salmon; Patrizia Carrieri; Maria Winnock; Marion Mora; Laurence Merchadou; Stéphanie Gillet; Elodie Pambrun; Jean Delaune; Marc-Antoine Valantin; Isabelle Poizot-Martin; Didier Neau; Philippe Bonnard; Eric Rosenthal; Karl Barange; Philippe Morlat; Karine Lacombe; Anne Gervais; François Rouges; Alain Bicart See; Caroline Lascoux-Combe; Daniel Vittecoq; Cécile Goujard; Claudine Duvivier; Bruno Spire; Jacques Izopet; Philippe Sogni; Lawrence Serfaty; Yves Benhamou; Firouzé Bani-Sadr; François Dabis
Journal:  BMC Infect Dis       Date:  2010-10-22       Impact factor: 3.090

Review 10.  Critical care of persons infected with the human immunodeficiency virus.

Authors:  Anuradha Ganesan; Henry Masur
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.